reports
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Ind...
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older Saint Herblain (France), August 18, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252. In addit...
Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé ...
Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus Saint-Herblain (France), le 18 août 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché pour son vaccin à dose unique, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya chez les personnes âgées de 12 ans et plus. Cette annonce s'ajoute à l'autorisation de mise sur le marché déjà obtenue au Canada pour les adultes1 et fait...
- Olfa Taamallah
- Yan Derocles
LXS LANXESS AG
GLB GLANBIA PLC
FTON FEINTOOL INTERNATIONAL HOLDING AG
ADN1 ADESSO AG
SQN SWISSQUOTE GROUP HOLDING AG
SAX STROEER SE & CO. KGAA
PYT POLYTEC HOLDING
POST OSTERREICHISCHE POST AG
SNG SOCIETATEA NATIONALA DE GAZE NATURALE ROMGAZ SA
DIGI DIGI COMMUNICATIONS NV
HFG HELLOFRESH SE
FAST FASTNED
AERO MONTANA AEROSPACE AG
SHUR SHURGARD SELF STORAGE LIMITED
NCH2 THYSSENKRUPP NUCERA AG & CO.
- Olfa Taamallah
- Yan Derocles
LXS LANXESS AG
GLB GLANBIA PLC
FTON FEINTOOL INTERNATIONAL HOLDING AG
ADN1 ADESSO AG
SAX STROEER SE & CO. KGAA
PYT POLYTEC HOLDING
POST OSTERREICHISCHE POST AG
SNG SOCIETATEA NATIONALA DE GAZE NATURALE ROMGAZ SA
DIGI DIGI COMMUNICATIONS NV
HFG HELLOFRESH SE
FAST FASTNED
AERO MONTANA AEROSPACE AG
SHUR SHURGARD SELF STORAGE LIMITED
NCH2 THYSSENKRUPP NUCERA AG & CO.
- Michael B. Schäfer
- Adrian Pehl
ISS ISS A/S
VLS VALNEVA SE
NOEJ NORMA GROUP SE
ROS ROSENBAUER INTERNATIONAL AG
INH INDUS HOLDING AG
TEG TAG IMMOBILIEN AG
COK CANCOM SE
TECN TECAN GROUP AG
TWEKA TKH GROUP N.V. CERT
JUN3 JUNGHEINRICH AG PREF
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
AEIN ALLGEIER HOLDING AG
FQT FREQUENTIS AG WIENER
ALLFG ALLFUNDS (UK) LTD
SCHOTT PHARMA AG
- Adrian Pehl
ISS ISS A/S
VLS VALNEVA SE
NOEJ NORMA GROUP SE
ROS ROSENBAUER INTERNATIONAL AG
INH INDUS HOLDING AG
TEG TAG IMMOBILIEN AG
COK CANCOM SE
TECN TECAN GROUP AG
TWEKA TKH GROUP N.V. CERT
JUN3 JUNGHEINRICH AG PREF
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
AEIN ALLGEIER HOLDING AG
FQT FREQUENTIS AG WIENER
ALLFG ALLFUNDS (UK) LTD
SCHOTT PHARMA AG
- Damien Choplain
- Oscar Haffen Lamm
Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4
Valneva delivered a solid H1 and reaffirmed its 2025 guidance. The company’s cash position, standing at €161m, is sufficient to fund operations through 2027e, providing solid financial visibility. Looking ahead, the next key catalyst is the Phase III data readout for VLA15, Valneva’s Lyme disease v
- Sinan Doganli
- Julian Dobrovolschi
Valneva Reports Half Year 2025 Financial Results and Provides Corporat...
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates Total revenues of €97.6 million compared to €70.8 million in the first half of 2024Cash and cash equivalents of €161.3 million at end of June 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), August 12, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year, ended June 30, 2025, and confirmed its 2025 financial guidance. The half year financial report...
Valneva publie ses résultats financiers du premier semestre 2025 et fa...
Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités Chiffre d’affaires de 97,6 millions d’euros contre 70,8 millions d’euros au premier semestre 2024Trésorerie de 161,3 millions d’euros à fin juin 2025Poursuite des avancées cliniques et réglementaires Confirmation des perspectives 2025 Saint-Herblain (France), le 12 août 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a publié aujourd’hui ses résultats financiers consolidés et condensés du premier semestre clos au 30 juin 2025. Le rapport financier semestri...
SMCP - Return of the shares to European Topsoho and clarification of s...
SMCP - Return of the shares to European Topsoho and clarification of shareholding situation Press release - Paris, August 11th, 2025 Proceedings in relation to the transfer of 15.5% of the share capital of SMCPReturn of the shares to European Topsoho and clarification of shareholding situation SMCP has been informed that, following the decision of the Singapore High Court on July 4th, 2025, the 15.5% stake of SMCP which had been transferred in 2021 to Dynamic Treasure Group has been returned to European Topsoho S.à r.l. (ETS) on August 11th, 2025. ETS was placed under bankruptcy p...
SMCP - Restitution des actions à European Topsoho et clarification de ...
SMCP - Restitution des actions à European Topsoho et clarification de la situation actionnariale Communiqué de presse - Paris, le 11 aout 2025 Contentieux relatif à la cession de 15,5% du capital de SMCPRestitution des actions à European Topsoho et clarification de la situation actionnariale SMCP a été informée que, à la suite à la décision de la Haute Cour de Singapour du 4 juillet 2025, la participation de 15,5% du capital de SMCP qui avait été cédée en 2021 à Dynamic Treasure Group a été restituée le 11 août 2025 à European Topsoho S.à r.l. (ETS). Pour mémoire, ETS a été placée ...
- Damien Choplain
- Oscar Haffen Lamm
Valneva : FDA lifts age restriction on IXCHIQ
Valneva announced yesterday that the FDA has lifted its recommended pause on the use of IXCHIQ in individuals aged 60+, following updated safety data. This follows a similar decision by the EMA in July, which lifted temporary restrictions after a safety review. Despite regulatory clearance from bot
Viscofan Sa: 1 director
A director at Viscofan Sa sold 7,400 shares at 61.000EUR and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungun...
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information Saint Herblain (France), August 7, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of a...
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisa...
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées et une mise à jour des caractéristiques du produit Saint Herblain (France), le 7 août 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui la levée de l’arrêt temporaire de l’agence de santé américaine Food and Drug Administration (FDA) sur l’utilisation d’IXCHIQ® (vaccin vivant atténué) chez les personnes âgées de 60 ans et plus ainsi que son accord sur une mise à jour des caractéristiques du produit....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.